ERBB2 and breast cancer: However, new targeted therapies, such as PARP inhibitors, immune checkpoint inhibitors (ICIs), and antibody−drug conjugates (e.g., sacituzumab−govitecan or trastuzumab deruxtecan in HER2 low BC) are now available5–8.